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Can We Predict Who Will Beneﬁt?*G. William Dec, MDSEE PAGE 2059T he recent U.S. Food and Drug Administra-tion approval of LCZ696, a combination ofsacubitril and valsartan, has generated
palpable excitement among heart failure (HF) clini-
cians (1). Several lines of evidence have pointed
to the potential beneﬁts of drugs combining renin-
angiotensin-aldosterone system inhibition with en-
hanced natriuretic peptide activity (2). Neprilysin, a
neutral endopeptidase (NEP), degrades endogenous
vasoactive peptides, including natriuretic peptides
and bradykinin. Neprilysin inhibition results in
higher levels of natriuretic peptides, producing vaso-
dilation, sodium excretion, and possible improve-
ment in ventricular remodeling (2). Small trials of
LCZ696 in patients with hypertension or HF with pre-
served ejection fraction demonstrated hemodynamic
and neurohormonal effects that were greater than
those observed by an angiotensin receptor blocker
alone (3).
The multinational, randomized PARADIGM-HF
(Prospective Comparison of ARNI and ACEI to Deter-
mine Impact on Global Mortality and Morbidity
in Heart Failure) trial directly compared LCZ696
with enalapril in 8,442 adult patients with New York
Heart Association (NYHA) functional class II to IV HF
symptoms and left ventricular ejection fractions
#35% receiving stable doses of beta-blocker and
angiotensin-converting enzyme inhibitor or angio-
tensin receptor blocker therapy (4).
The trial was stopped early for clinical beneﬁt,
with a hazard ratio for the primary endpoint of*Editorials published in the Journal of the American College of Cardiology
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to the contents of this paper to disclose.cardiovascular death or HF hospitalization of 0.80
(95% conﬁdence interval: 0.71 to 0.89). Although
LCZ696 was more frequently associated with symp-
tomatic hypotension, this did not lead to a higher
frequency of drug discontinuation. Renal dysfunc-
tion, hyperkalemia, and cough occurred signiﬁcantly
less frequently with LCZ696 than with enalapril.
However, a nonsigniﬁcant trend for an increase in
angioedema with LCZ696 was noted (p ¼ 0.13). Packer
et al. (5) subsequently demonstrated additional clin-
ical beneﬁt of LCZ696, including a reduced need for
intensiﬁed HF therapy, inotropic agents, mechanical
circulatory support, or heart transplantation. Sus-
tained reductions in myocardial biomarkers (troponin
and N-terminal pro-B-type natriuretic peptide [BNP])
were also observed (5).In this issue of the Journal, Simpson et al. (6) report
the results of a post-hoc analysis of PARADIGM-HF to
examine the spectrum of risk among trial participants
and LCZ696’s effect across that spectrum. Although
most patients were classiﬁed as having mild symp-
toms (5% in NYHA functional class I and 70% in NYHA
functional class II), the correlation between self-
reported functional limitation and long-term prog-
nosis in chronic systolic HF is often poor. Thus, NYHA
classiﬁcation encompasses a wide and overlapping
range of risks. The investigators calculated baseline
prognostic risk using 2 previously validated HF
scoring systems: the MAGGIC (Meta-Analysis Global
Group in Chronic Heart Failure) score and the
EMPHASIS-HF (Eplerenone in Mild Patients Hospi-
talization and Survival Study in Heart Failure) score
(7,8).
The investigators sought to answer the pivotal
question of whether risk based on these clinically
validated scores modiﬁed LCZ696’s treatment.
The MAGGIC risk score identiﬁed 13 independent
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2073predictors of all-cause mortality, including age, male
sex, diabetes, systolic blood pressure, left ventricular
ejection fraction, obstructive lung disease, renal
dysfunction, and the use of neurohormonal antago-
nists (7). A simple integer score was derived for each
patient, with a maximum of 57 points. Similarly, the
EMPHASIS-HF risk score included 10 independent
risk factors, such as hemoglobin, heart rate, and prior
HF hospitalization; the maximal possible score was 12
points (8). Patients were divided into 5 quintiles of
MAGGIC risk and 4 quartiles of EMPHASIS-HF risk.
The primary composite endpoint of death or HF
hospitalization, those 2 components, and all-cause
mortality were all analyzed for each risk group and
by treatment type using Cox regression modeling.
Not surprisingly, patients in higher quintiles were
more likely to have NYHA functional class III or IV
symptoms and additional medical comorbidities.
When the MAGGIC score was examined as a contin-
uous variable, an increase of 1 point in the overall
score was associated with a 6% increased risk for the
primary endpoint and a 7% increased risk for cardio-
vascular death. Importantly, the beneﬁt of LCZ696
over enalapril for the primary endpoint was similar
across the entire spectrum of risk. Analysis using
the EMPHASIS-HF score produced similar ﬁndings.
Whether analyzed as continuous or categorical vari-
ables, LCZ696 provided the greatest absolute beneﬁt
in those at highest risk. The investigators conclude
that, within the overall PARADIGM-HF population,
there was a substantial subset with much to gain from
angiotensin receptor and neprilysin inhibition over a
relatively short period of time (6).
Although these ﬁndings are impressive, various
limitations must be considered. First and foremost,
this was a non-pre-speciﬁed post-hoc analysis with
the inherent limitations and potential for unrecog-
nized bias. In addition, trial patients were generally
younger (mean age 64 years), had better preserved
systolic blood pressures, and had less renal dys-
function than many “real-life” HF populations.
Furthermore, neither prognostic risk score included
natriuretic peptide biomarkers, which are powerful
predictors of outcome. Also, the MAGGIC score was
developed to estimate all-cause mortality, not to
stratify patients for other outcomes such as HF hos-
pitalizations. Unlike angiotensin-converting enzyme
inhibitors, LCZ696 has not yet been demonstrated to
produce favorable effects on ventricular remodeling.
The safety of introducing LCZ696 during hospitali-
zation for acute decompensated HF has yet to
be systematically assessed. Finally, it is increasingly
common that serum biomarkers such as BNP,
N-terminal pro-BNP, and ST2 are used in clinicalpractice to guide pharmacological intensiﬁcation.
Whether these biomarkers can be used to monitor
treatment efﬁcacy remains unknown.
Assays for quantitative measurement of soluble
serum neprilysin (sNEP) levels and NEP catalytic
activity have recently become available. sNEP levels
have been shown to predict short- and long-term
prognosis in acute decompensated HF, independent
of N-terminal pro-BNP (9). Importantly, there appears
to be substantial biologic “crosstalk” between circu-
lating natriuretic peptides and NEP activity. Vodovar
et al. (10) demonstrated in patients with acute HF that
elevated immunoreactive BNP (BNP plus N-terminal
pro-BNP) levels >916 pg/ml signiﬁcantly inhibit NEP’s
catalytic activity. This new ﬁnding raises concern
about whether patients with chronic advanced HF,
typically characterized by very high BNP levels, may
have an attenuated clinical response to an exogenous
NEP inhibitor such as LCZ696 because of suppression
of NEP catalytic activity (11). Future studies should
examine whether either sNEP levels or NEP activity
may help clinicians identify those patients most likely
to respond to LCZ696 and whether serial measure-
ment of these novel biomarkers may help optimize
dosing (11).
Finally, 2 safety concerns that were not fully
addressed in this study are undergoing evaluation.
Angioedema, which was ﬁrst observed with the
angiotensin-converting enzyme and neprilysin in-
hibitor omapatrilat, was expected to be eliminated
using the angiotensin receptor blocker and neprily-
sin inhibitor. However, angioedema was more
frequently reported in the LCZ696 cohort (19 cases)
than the enalapril cohort (10 cases). The exact fre-
quency of this adverse event remains to be quan-
tiﬁed. Additionally, beta-amyloid is also a
recognized substrate for neprilysin; its inhibition
may block the breakdown of this key peptide
that has been implicated in the pathogenesis and
progression of Alzheimer’s disease. Cognitive func-
tional changes will require serial assessment
during long-term treatment, particularly in elderly
patients.
The investigators have provided valuable infor-
mation suggesting that this new class of pharmaco-
logical inhibitor can produce major beneﬁts in a
wide spectrum of patients with systolic HF. For the
practicing clinician, several unanswered question
remain. First, should circulating sNEP levels and/or
NEP catalytic activity be routinely measured and used
to guide LCZ696 therapeutic decisions? Second,
which patients in stable condition should be switched
from their current renin-angiotensin-aldosterone
system inhibitors to LCZ696? Unlike clinical practice,
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during which tolerability was carefully assessed.
Despite the exclusion of numerous potential study
candidates, symptomatic hypotension remained
greater in the LCZ696 group. This suggests that pa-
tients with borderline blood pressures or those
tolerating lower than recommended doses of vaso-
dilator therapy may encounter difﬁculties with
LCZ696. The MAGGIC and EMPHASIS-HF scores help
predict prognosis but do not aid in optimizing patient
selection. It would appear that patients with mild
to moderate HF and adequate systolic blood pressures
on maintenance renin-angiotensin-aldosterone systeminhibitor therapy would be most suited for transition to
this new agent. Establishing the optimal regimen for
conversion and up-titration of LCZ696 remains a short-
term challenge.
Nonetheless, this is a good “problem” to have,
as a new class of agents with major beneﬁts is on
the horizon and should substantially improve our
approach to managing chronic systolic HF.
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